 | Up a level |
2019
Morgensztern, Daniel, Besse, Benjamin, Greillier, Laurent 
ORCID: 0000-0002-5807-9503, Santana-Davila, Rafael, Ready, Neal, Hann, Christine L., Glisson, Bonnie S., Farago, Anna F., Dowlati, Afshin, Rudin, Charles M., Le Moulec, Sylvestre, Lally, Satwant, Yalamanchili, Sreeni, Wolf, Juergen, Govindan, Ramaswamy and Carbone, David P.
(2019).
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
Clin. Cancer Res., 25 (23).
S. 6958 - 6967.
PHILADELPHIA:
AMER ASSOC CANCER RESEARCH.
ISSN 1557-3265
2018
Carbone, David Paul, Morgensztern, Daniel, Le Moulec, Sylvestre, Santana-Davila, Rafael, Ready, Neal, Hann, Christine L., Glisson, Bonnie S., Dowlati, Afshin, Rudin, Charles M., Lally, Satwant, Yalamanchili, Sreeni, Wolf, Juergen, Govindan, Ramaswamy and Besse, Benjamin (2018). Efficacy and safety of rovalpituzumab tesirine in patients With DLL3-expressing, >= 3rd line small cell lung cancer: Results from the phase 2 TRINITY study. J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755